Theranostics in Oncology—Thriving, Now More than Ever
Abstract
:Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Chapman, E.M.; Evans, R.D. The treatment of hyperthyroidism with radioactive iodine. JAMA 1946, 11, 186. [Google Scholar]
- Schlumberger, M.; Catargi, B.; Borget, I.; Deandreis, D.; Zerdoud, S.; Bridji, B.; Bardet, S.; Leenhardt, L.; Bastie, D.; Schvartz, C.; et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 2012, 366, 1663–1673. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weber, W.A.; Czernin, J.; Anderson, C.J.; Badawi, R.D.; Barthel, H.; Bengel, F.; Bodei, L.; Buvat, I.; DiCarli, M.; Graham, M.M.; et al. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. J. Nucl. Med. 2020, 61, 263S–272S. [Google Scholar] [CrossRef] [PubMed]
- Solnes, L.B.; Werner, R.A.; Jones, K.M.; Sadaghiani, M.S.; Bailey, C.R.; Lapa, C.; Pomper, M.G.; Rowe, S.P. Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine. J. Nucl. Med. 2020, 61, 311–318. [Google Scholar] [CrossRef]
- Strosberg, J.; El-Haddad, G.; Wolin, E.; Hendifar, A.; Yao, J.; Chasen, B.; Mittra, E.; Kunz, P.L.; Kulke, M.H.; Jacene, H.; et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N. Engl. J. Med. 2017, 376, 125–135. [Google Scholar] [CrossRef] [PubMed]
- Hofman, M.S.; Violet, J.; Hicks, R.J.; Ferdinandus, J.; Thang, S.P.; Akhurst, T.; Iravani, A.; Kong, G.; Ravi Kumar, A.; Murphy, D.G.; et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol. 2018, 19, 825–833. [Google Scholar] [CrossRef]
- Hofman, M.S.; Emmett, L.; Sandhu, S.; Iravani, A.; Joshua, A.M.; Goh, J.C.; Pattison, D.A.; Tan, T.H.; Kirkwood, I.D.; Ng, S.; et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial. Lancet 2021, 397, 797–804. [Google Scholar] [CrossRef]
- Wakabayashi, H.; Kayano, D.; Inaki, A.; Araki, R.; Kuroda, R.; Akatani, N.; Yamase, T.; Watanabe, S.; Hiromasa, T.; Kunita, Y.; et al. Diagnostic Use of Post-therapy (131)I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma. Diagnostics 2020, 10, 663. [Google Scholar] [CrossRef] [PubMed]
- Werner, R.A.; Weich, A.; Kircher, M.; Solnes, L.B.; Javadi, M.S.; Higuchi, T.; Buck, A.K.; Pomper, M.G.; Rowe, S.P.; Lapa, C. The theranostic promise for Neuroendocrine Tumors in the late 2010s—Where do we stand, where do we go? Theranostics 2018, 8, 6088–6100. [Google Scholar] [CrossRef]
- Ohlendorf, F.; Werner, R.A.; Henkenberens, C.; Ross, T.L.; Christiansen, H.; Bengel, F.M.; Derlin, T. Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy. Diagnostics 2021, 11, 504. [Google Scholar] [CrossRef]
- Pavel, M.; Valle, J.W.; Eriksson, B.; Rinke, A.; Caplin, M.; Chen, J.; Costa, F.; Falkerby, J.; Fazio, N.; Gorbounova, V.; et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy—Biotherapy and Novel Targeted Agents. Neuroendocrinology 2017, 105, 266–280. [Google Scholar] [CrossRef] [PubMed]
- Wetz, C.; Rogasch, J.; Genseke, P.; Schatka, I.; Furth, C.; Kreissl, M.; Jann, H.; Venerito, M.; Amthauer, H. Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment? Diagnostics 2020, 10, 732. [Google Scholar] [CrossRef]
- Rinke, A.; Gress, T.M. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers. Digestion 2017, 95, 109–114. [Google Scholar] [CrossRef] [PubMed]
- Maurer, S.; Herhaus, P.; Lippenmeyer, R.; Hanscheid, H.; Kircher, M.; Schirbel, A.; Maurer, H.C.; Buck, A.K.; Wester, H.J.; Einsele, H.; et al. Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. J. Nucl. Med. 2019, 60, 1399–1405. [Google Scholar] [CrossRef] [Green Version]
- Herrmann, K.; Schottelius, M.; Lapa, C.; Osl, T.; Poschenrieder, A.; Hanscheid, H.; Luckerath, K.; Schreder, M.; Bluemel, C.; Knott, M.; et al. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. J. Nucl. Med. 2016, 57, 248–251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weich, A.; Rogoll, D.; Gawlas, S.; Mayer, L.; Weich, W.; Pongracz, J.; Kudlich, T.; Meining, A.; Scheurlen, M. Wnt/beta-Catenin Signaling Regulates CXCR4 Expression and [(68)Ga] Pentixafor Internalization in Neuroendocrine Tumor Cells. Diagnostics 2021, 11, 367. [Google Scholar] [CrossRef]
- Weich, A.; Werner, R.A.; Buck, A.K.; Hartrampf, P.E.; Serfling, S.E.; Scheurlen, M.; Wester, H.J.; Meining, A.; Kircher, S.; Higuchi, T.; et al. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics 2021, 11, 605. [Google Scholar] [CrossRef]
- Mirian, C.; Duun-Henriksen, A.K.; Maier, A.; Pedersen, M.M.; Jensen, L.R.; Bashir, A.; Graillon, T.; Hrachova, M.; Bota, D.; van Essen, M.; et al. Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. J. Nucl. Med. 2021, 62, 507–513. [Google Scholar] [CrossRef]
- Graef, J.; Senger, C.; Wetz, C.; Baur, A.D.J.; Kluge, A.K.; Lukas, M.; Rogasch, J.M.M.; Walter-Rittel, T.C.; Kohnert, D.; Makowski, M.; et al. Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition. Diagnostics 2020, 10, 84. [Google Scholar] [CrossRef]
- Sheikhbahaei, S.; Afshar-Oromieh, A.; Eiber, M.; Solnes, L.B.; Javadi, M.S.; Ross, A.E.; Pienta, K.J.; Allaf, M.E.; Haberkorn, U.; Pomper, M.G.; et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 2117–2136. [Google Scholar] [CrossRef]
- Eiber, M.; Herrmann, K.; Calais, J.; Hadaschik, B.; Giesel, F.L.; Hartenbach, M.; Hope, T.; Reiter, R.; Maurer, T.; Weber, W.A.; et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J. Nucl. Med. 2018, 59, 469–478. [Google Scholar] [CrossRef] [Green Version]
- Ceci, F.; Oprea-Lager, D.E.; Emmett, L.; Adam, J.A.; Bomanji, J.; Czernin, J.; Eiber, M.; Haberkorn, U.; Hofman, M.S.; Hope, T.A.; et al. E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur. J. Nucl. Med. Mol. Imaging 2021. [Google Scholar] [CrossRef] [PubMed]
- Rowe, S.P.; Pienta, K.J.; Pomper, M.G.; Gorin, M.A. PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. Eur. Urol. 2018, 73, 485–487. [Google Scholar] [CrossRef]
- Khatri, W.; Chung Woo, H.; Werner, R.A.; Leal, J.P.; Peinta, K.J.; Lodge, M.A.; Gorin, M.A.; Pomper, M.G.; Rowe, S.P. Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer. Diagnostics 2021, 11, 665. [Google Scholar] [CrossRef]
- Volter, F.; Mittlmeier, L.; Gosewisch, A.; Brosch-Lenz, J.; Gildehaus, F.J.; Zacherl, M.J.; Beyer, L.; Stief, C.G.; Holzgreve, A.; Rubenthaler, J.; et al. Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after (177)Lu-PSMA-617 Radioligand Therapy. Diagnostics 2021, 11, 428. [Google Scholar] [CrossRef]
- Lassmann, M.; Eberlein, U. The Relevance of Dosimetry in Precision Medicine. J. Nucl. Med. 2018, 59, 1494–1499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moazemi, S.; Erle, A.; Lutje, S.; Gaertner, F.C.; Essler, M.; Bundschuh, R.A. Estimating the Potential of Radiomics Features and Radiomics Signature from Pretherapeutic PSMA-PET-CT Scans and Clinical Data for Prediction of Overall Survival When Treated with (177)Lu-PSMA. Diagnostics 2021, 11, 186. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Werner, R.A.; Higuchi, T.; Pomper, M.G.; Rowe, S.P. Theranostics in Oncology—Thriving, Now More than Ever. Diagnostics 2021, 11, 805. https://doi.org/10.3390/diagnostics11050805
Werner RA, Higuchi T, Pomper MG, Rowe SP. Theranostics in Oncology—Thriving, Now More than Ever. Diagnostics. 2021; 11(5):805. https://doi.org/10.3390/diagnostics11050805
Chicago/Turabian StyleWerner, Rudolf A., Takahiro Higuchi, Martin G. Pomper, and Steven P. Rowe. 2021. "Theranostics in Oncology—Thriving, Now More than Ever" Diagnostics 11, no. 5: 805. https://doi.org/10.3390/diagnostics11050805